MedPath

Diazoxide

Generic Name
Diazoxide
Brand Names
Proglycem
Drug Type
Small Molecule
Chemical Formula
C8H7ClN2O2S
CAS Number
364-98-7
Unique Ingredient Identifier
O5CB12L4FN

Overview

Diazoxide is a non-diuretic benzothiadiazine derivative that activates ATP-sensitive potassium channels. It is chemically related to thiazide diuretics but does not inhibit carbonic anhydrase and does not have chloriuretic or natriuretic activity. Diazoxide is commonly used in the treatment of hyperinsulinaemic hypoglycemia due to its ability to inhibit insulin release. Diazoxide also exhibits hypotensive activity and reduces arteriolar smooth muscle and vascular resistance. When administered intravenously, diazoxide can be used to treat hypertensive emergencies; however, this specific form of diazoxide is no longer available in the US. Diazoxide is usually well tolerated, and some of its more common side effects include fluid retention and electrolyte disturbances. In September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates.

Background

Diazoxide is a non-diuretic benzothiadiazine derivative that activates ATP-sensitive potassium channels. It is chemically related to thiazide diuretics but does not inhibit carbonic anhydrase and does not have chloriuretic or natriuretic activity. Diazoxide is commonly used in the treatment of hyperinsulinaemic hypoglycemia due to its ability to inhibit insulin release. Diazoxide also exhibits hypotensive activity and reduces arteriolar smooth muscle and vascular resistance. When administered intravenously, diazoxide can be used to treat hypertensive emergencies; however, this specific form of diazoxide is no longer available in the US. Diazoxide is usually well tolerated, and some of its more common side effects include fluid retention and electrolyte disturbances. In September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates.

Indication

Oral diazoxide is indicated to manage hypoglycemia due to hyperinsulinism associated with conditions such as inoperable islet cell adenoma or carcinoma, and extrapancreatic malignancy in adults, or leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, and adenomatosis in infants and children. In infants and children oral diazoxide may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. Diazoxide may also be used parentally or intravenously to treat hypertensive emergencies.

Associated Conditions

  • Hyperinsulinemic Hypoglycemia

FDA Approved Products

Diazoxide
Manufacturer:e5 Pharma, LLC
Route:ORAL
Strength:50 mg in 1 mL
Approved: 2023/05/03
NDC:13517-100
Proglycem
Manufacturer:Teva Pharmaceuticals USA, Inc.
Route:ORAL
Strength:50 mg in 1 mL
Approved: 2023/03/29
NDC:0575-6200
Diazoxide
Manufacturer:Par Pharmaceutical, Inc
Route:ORAL
Strength:50 mg in 1 mL
Approved: 2023/03/08
NDC:0254-1010

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath